MedTrace Logo

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

NCT00596271 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2014-05-13

Study results available
· View outcomes & findings →

Summary

The objective is to investigate the immunogenicity of the Japanese Encephalitis vaccine IC51 (JE-PIV) single and concomitant with HAVRIX® 1440

Conditions

  • Japanese Encephalitis

Interventions

BIOLOGICAL

IC51

BIOLOGICAL

HAVRIX

OTHER

Placebo

Sponsors & Collaborators

  • Valneva Austria GmbH

    lead INDUSTRY

Principal Investigators

  • Astrid Kaltenboeck, Ph.D. · Valneva Austria GmbH

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2006-07-31
Completion
2008-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00596271 on ClinicalTrials.gov